Revlimid® (lenalidomide) – New indications
May 28, 2019 - Celgene announced the FDA approval of Revlimid (lenalidomide), in combination with a rituximab (Rituxan®) product for the treatment of adult patients with previously treated follicular lymphoma (FL) and marginal zone lymphoma (MZL).
Download PDF
